Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. director Mayron Ron filed an initial Form 3, detailing existing equity holdings rather than new trades. Ron holds 296,631 ordinary shares, consisting of 10,000 shares and 286,631 restricted share units, of which 107,486 have vested and 179,631 remain unvested as of March 18, 2026.
Ron also reports several fully vested share option grants over the company’s ordinary shares: 95,295 options at an exercise price of $1.55 per share expiring in 2028, 25,000 at $1.79 expiring in 2029, 25,000 at $1.68 expiring in 2030, and 110,000 at $3.64 expiring in 2032. An additional 59,295 options at $1.51 per share expiring in 2033 are partly vested, with 44,471 options vested as of March 18, 2026. This filing simply records Ron’s current ownership position.
IceCure Medical Ltd. officer Naum Muchnik, VP of R&D & Engineering, reports his current equity holdings in the company. He holds 118,621 ordinary shares directly, with no buy or sell transactions reported in this filing.
He also holds multiple option grants over ordinary shares, including 4,142 options at an exercise price of $2.27 per share expiring in 2029, 16,000 options at $1.79 expiring in 2029, 27,462 options at $1.56 expiring in 2030, 1,318 options at $5.78 expiring in 2031, 80,668 options at $3.64 expiring in 2032, 4,085 options at $2.84 expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 90,945 options at $0.92 expiring in 2034.
Footnotes state that earlier grants are fully vested as of March 18, 2026, while more recent option and restricted share unit awards vest over time, with portions already vested and the remainder scheduled to vest in equal quarterly installments.
IceCure Medical Ltd. VP of Human Resources Dotan Merav Nir filed a Form 3 disclosing existing equity holdings in the company. The filing shows direct ownership of 68,814 ordinary shares, made up of 500 shares and 68,314 unvested restricted stock units granted in 2024, 2025, and 2026 as of March 18, 2026.
Nir also holds share options over 80,668 ordinary shares at an exercise price of $3.64 per share fully vested and expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 27,283 options at $0.92 expiring in 2034. The Form 3 records these positions only, with no reported purchases or sales.
IceCure Medical Ltd. filed an initial ownership report for Chief Executive Officer Eyal Shamir, detailing his existing equity position. As of March 18, 2026, he directly holds 791,381 ordinary shares, plus a range of vested and unvested equity awards.
Footnotes show additional exposure through restricted share units granted on May 15, 2025; November 5, 2025; and March 16, 2026, with portions vesting in 25% cliffs and 6.25% quarterly installments thereafter. Shamir also holds multiple fully or partially vested share options over ordinary shares with exercise prices converted from Israeli shekels into U.S. dollars, including options over 117,551 shares at an exercise price of $0.82 per share expiring January 23, 2027, and several later grants expiring between 2028 and 2033. The filing records these as holdings only, with no reported recent purchases, sales, or option exercises.
IceCure Medical reported positive 5‑year top-line results from its ICESECRET study of the ProSense® cryoablation system in kidney cancer. At a median follow-up of four years, 83.9% of the 112 evaluated patients with small renal masses were recurrence-free based on imaging.
In a subgroup with tumors ≤3 cm, no prior kidney cancer and successful initial procedures, the recurrence-free rate reached 89.4%. The trial enrolled 114 patients across two centers in Israel, and full data are expected to be presented at the European Conference on Interventional Oncology 2026 in Basel.
IceCure Medical appointed Meir Peleg as Chief Financial Officer, with his employment beginning on May 17, 2026, under an employment agreement and standard indemnification terms used for its directors and executives. He brings over 20 years of financial leadership, including experience as a Nasdaq-listed company CFO.
The company reported the resignation of its Vice President of R&D and Engineering, Naum Muchnik, effective April 12, 2026. IceCure also plans to appoint breast surgical oncologist Dr. Richard E. Fine as Medical Director in the second quarter of 2026, supporting breast cryoablation clinical and educational initiatives.
IceCure Medical Ltd. filed an amendment to its Form F-3 shelf registration to register up to $100,000,000 of Ordinary Shares, warrants or units, to be offered from time to time after the effective date hereof. The prospectus supplements will state the specific offering terms, prices and proceeds treatment for each sale.
The prospectus notes 73,122,293 Ordinary Shares issued and outstanding as of December 31, 2025, cash and cash equivalents of $8,897,000 as of that date, and lists issuable securities including options, RSUs and warrants from the Rights Offering.
IceCure Medical Ltd. files a post-effective amendment to permit issuance of up to 9,744,072 ordinary shares upon exercise of outstanding warrants and pre-funded warrants.
The shares comprise warrants exercisable at $1.00 and pre-funded warrants exercisable at $0.0001. If fully exercised, the company expects to receive net proceeds of approximately $9.7 million. The prospectus states 73,180,045 Ordinary Shares outstanding as of March 20, 2026 and an as‑adjusted post‑exercise share count shown in the offering materials. The amendment updates the prospectus and covers issuance of Ordinary Shares underlying unexercised warrants; no additional securities are being registered.